Trial Profile
Multicenter Double Blind Randomized Clinical Trial Assessing the Benefit of Adherent Invasive E. Coli Eradication in Adult Ileal and Ileo-colonic Crohn Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Ciprofloxacin (Primary) ; Rifaximin (Primary)
- Indications Crohn's disease; Escherichia coli infections
- Focus Therapeutic Use
- Acronyms TEOREM
- 21 Aug 2023 Status changed from recruiting to discontinued due to insufficient recruitment.
- 23 Jun 2016 Status changed from not yet recruiting to recruiting.
- 04 Dec 2015 New trial record